ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Five-year real-world outcomes and patterns of MNV-related atrophy after anti-VEGF therapy in eyes with pathologic myopia.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe investigated the long-term visual and structural outcomes in eyes with myopic macular neovascularization (MNV) treated with anti-vascular endothelial growth factor (VEGF) therapy and focused on developmental patterns and associated factors of MNV-related atrophy.
methodsThis retrospective, observational study included 39 eyes with treatment-naïve myopic MNV who received intravitreal ranibizumab or aflibercept and were followed for at least 5 years. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), and central choroidal thickness (CCT) were measured longitudinally. Color fundus photography classified the atrophy as perilesional and foveal. Factors associated with atrophy and final BCVA were analyzed.
resultsOver 5 years, the mean BCVA significantly improved from baseline and remained significantly better at all time points (P < 0.05); the CRT and CCT decreased significantly from baseline (P < 0.05). MNV-related atrophy developed in 59% of eyes and foveal atrophy in 38%. Three atrophic types were identified: perilesional (74%), patchy atrophy expansion (22%), and atrophy following subretinal hemorrhage (4%). Perilesional atrophy developed in older patients. Eyes with perilesional or foveal atrophy had worse baseline BCVA, thicker baseline CRT, larger greatest linear dimension, more frequent Meta-Analysis for Pathologic Myopia category 3, subfoveal MNV, and more injections than without atrophy, although none remained significant in multivariate analysis. Multivariate analysis showed foveal atrophy to be the strongest determinant of poorer BCVA.
conclusionAnti-VEGF therapy was associated with favorable long-term visual outcomes in myopic MNV. However, MNV-related atrophy, particularly foveal atrophy, was associated with visual decline. The presence of multiple atrophic patterns may suggest heterogeneous underlying mechanisms.
Indexed as
Identifiers
42257701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.